查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2148950

糖尿病神經病變市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測

Diabetic Neuropathy Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

糖尿病神經病變市場成長要素

全球糖尿病神經病變市場預計2025年達到51.5億美元，2026年達到56億美元，到2034年達到110.6億美元。推動該市場成長的因素包括糖尿病盛行率的上升、人們對糖尿病併發症的認知不斷提高、醫療保健支出增加以及先進療法和藥物傳輸技術的引入。北美地區預計將在2025年佔市場主導地位，市佔率高達60.66%，主要得益於其較高的糖尿病盛行率、先進的醫療保健基礎設施以及對創新療法的早期應用。

市場定義和範圍

糖尿病性神經病變是一種與糖尿病相關的神經病變，主要由長期高血糖引起。它不僅會影響腿部和足部的周邊神經，還會影響參與消化、泌尿功能、心血管活動和其他身體功能的神經。目前市面上的治療產品和療法涵蓋了針對周邊神經病變、自主神經病變、近端神經病變和局部神經病變的治療方案。糖尿病盛行率的上升、人口老化以及對有效疼痛管理療法日益成長的需求，都正在擴大市場前景。

市場趨勢

一種技術先進的藥物傳輸系統

技術先進的藥物傳遞系統的發展是影響糖尿病神經病變市場的關鍵趨勢。製造商正增加對經皮吸收貼片、口服製劑、口腔噴霧、粉末和無針注射技術的研究，以提高患者的便利性並減少傳統侵入性治療帶來的不適。對更人性化給藥方式的日益重視正促使製藥公司加強研發。

市場動態

促進因素

糖尿病患者數量增加

全球糖尿病患者人數的增加是推動市場成長的主要動力。久坐的生活方式、肥胖、不健康的飲食習慣、都市化以及血糖控制不佳等因素，都導致了糖尿病及其相關神經併發症發病率的上升。人們對早期診斷和治療意識的提高，也促使更多患者尋求神經病變的治療。

推出先進產品

製藥公司正透過推出新的疼痛管理藥物和創新療法來拓展產品系列。持續的研發投入、不斷成長的醫療保健支出以及對有效療法日益成長的需求，都為製藥企業創造了商機。

阻礙因素

高昂的醫療費用和替代療法

某些神經病變藥物的高昂價格會限制其普及，尤其是在價格敏感型市場。物理治療和其他輔助療法等替代方法也能減少對藥物的依賴。此外，嚴格的監管要求、產品召回和批准延遲也會影響產品上市。

細分分析

依疾病類型

這種市場細分將糖尿病神經病變分為周邊神經病變、自主神經病變、近端神經病變和局部神經病變。周邊神經病變佔市場主導地位，因為它是糖尿病神經病變的常見類型，尤其會影響腿部和足部。人們對周邊神經病變的認知不斷提高，診斷率也隨之上升，從而推動了對周邊神經病變治療的需求。由於糖尿病患者人數不斷增加，以及對安全有效治療方法的需求日益成長，自主神經病變市場也預計將呈現強勁成長。

藥物類別

該市場包括非類固醇消炎劑（ NSAIDs）、鴉片類藥物、抗憂鬱症和抗驚厥藥。由於非類固醇消炎劑在疼痛和發炎治療方面應用廣泛，因此佔市場主導地位。隨著新型疼痛管理製劑和療法的出現，鴉片類藥物市場預計將顯著成長。

透過分銷管道

市場可細分為醫院藥局、零售藥局和網路藥局。預計到2025年，醫院藥局將佔46.2%的市場佔有率，這主要得益於越來越多的糖尿病患者在醫院接受定期監測和治療。網路藥局的重要性也不斷提升，因為它們為患者提供了便捷的購藥途徑。

區域分析

北美洲

北美地區憑藉其高糖尿病盛行率、先進的醫療基礎設施、對創新療法的早期應用以及積極的藥物研發，繼續引領區域市場。美國由於確診糖尿病患者數量龐大，佔了區域需求的大部分佔有率。

歐洲

歐洲是全球第二大市場區域。醫療保健支出不斷成長、人口老化、糖尿病盛行率上升以及藥物研發活動都在推動市場發展。隨著人們對糖尿病併發症的認知不斷提高，預計該地區將保持穩定成長。

亞太地區

由於糖尿病盛行率上升、肥胖相關併發症增加、醫療基礎設施改善、政府宣傳活動以及先進藥物的廣泛應用，亞太地區預計將經歷最快的成長。預計中國市場將出現強勁成長。

日本

由於人口老化和糖尿病發生率上升，日本正成為一個重要的市場。受對有效治療神經病變疼痛的需求不斷成長的推動，預計到2025年，日本糖尿病神經病變市場規模將達到2.183億美元。

拉丁美洲、中東和非洲

預計拉丁美洲、中東和非洲地區將逐步發展。儘管醫療基礎設施不足、認知度低和資金籌措匱乏仍然是挑戰，但改善醫療服務可近性和加強糖尿病管理有望創造未來的機會。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇

第4章：主要考慮因素

  • 併購、收購和合作等主要產業趨勢
  • 新產品發布
  • 糖尿病神經病變的盛行率
  • 管道分析

第5章：2021-2034年全球糖尿病神經病變市場分析、洞察與預測

  • 主要發現與總結
  • 市場分析、洞察與預測：按疾病類型分類
    • 外圍
    • 自主神經系統
    • 近端型
    • 地點
  • 市場分析、洞察與預測：按藥物類別分類
    • 非類固醇消炎劑
    • 鴉片類藥物
    • 抗憂鬱症
    • 抗癲癇藥物
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥局和商店
    • 網路藥房
  • 市場分析、洞察與預測：按國家/地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美糖尿病神經病變市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲糖尿病神經病變市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區糖尿病神經病變市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲糖尿病神經病變市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲糖尿病神經病變市場分析、洞察與預測（2021-2034年）

  • 國家
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 主要行業趨勢
  • 全球市佔率分析（2025 年）
  • 競爭對手儀表板
  • 主要公司比較分析
  • 公司簡介
    • Abbott
    • Eli Lilly and Company
    • Pfizer.Inc
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc.
    • Janssen Pharmaceuticals, Inc.
    • Lupin Pharmaceuticals, Inc.
    • Astellas Pharma US, Inc.
    • Other Prominent Players

第12章 戰略建議

Product Code: FBI100598

Growth Factors of diabetic neuropathy Market

The global diabetic neuropathy market size was valued at USD 5.15 billion in 2025 and is projected to reach USD 5.60 billion in 2026 and USD 11.06 billion by 2034. The market is being driven by the increasing prevalence of diabetes, growing awareness of diabetic nerve complications, rising healthcare expenditure, and the introduction of advanced treatment and drug-delivery technologies. North America dominated the market with a 60.66% share in 2025, supported by a high diabetes burden, advanced healthcare infrastructure, and early adoption of innovative therapies.

Market Definition and Scope

Diabetic neuropathy is a diabetes-related nerve disorder caused primarily by prolonged elevated blood glucose levels. It can affect peripheral nerves in the legs and feet as well as nerves associated with digestion, urinary function, cardiovascular activity, and other bodily systems. The market includes therapeutic products and treatment approaches targeting peripheral, autonomic, proximal, and focal neuropathy. Growing diabetes prevalence, an aging population, and increasing demand for effective pain-management therapies are expanding the market outlook.

Market Trends

Technologically Advanced Drug Delivery Systems

The development of technologically advanced drug-delivery systems is an important trend shaping the diabetic neuropathy market. Manufacturers are increasingly exploring transdermal patches, oral formulations, mouth sprays, powders, and needle-free injection technologies to improve patient convenience and reduce discomfort associated with conventional invasive therapies. The growing focus on patient-friendly administration methods is encouraging pharmaceutical companies to strengthen research and product development activities.

Market Dynamics

Drivers

Rising Prevalence of Diabetes

The increasing global diabetic population is a major factor supporting market growth. Sedentary lifestyles, obesity, unhealthy dietary habits, urbanization, and inadequate glucose control contribute to the rising incidence of diabetes and related nerve complications. Increasing awareness about early diagnosis and treatment is also encouraging patients to seek neuropathy therapies.

Launch of Advanced Products

Pharmaceutical companies are expanding their portfolios through new pain-management drugs and innovative therapies. Continued research and development, increasing healthcare expenditure, and growing demand for effective treatment options are creating opportunities for manufacturers.

Restraints

High Treatment Costs and Alternative Therapies

High costs associated with certain neuropathy medications can restrict adoption, particularly in price-sensitive markets. Alternative approaches such as physiotherapy and other supportive treatments may also reduce dependence on pharmaceutical therapies. In addition, stringent regulatory requirements, product recalls, and delays in approvals can affect product launches.

Segmentation Analysis

By Disease Type

The market is segmented into peripheral, autonomic, proximal, and focal diabetic neuropathy. The peripheral segment dominated the market because it represents a common form of diabetic nerve damage, particularly affecting the legs and feet. Increasing awareness and diagnosis are supporting demand for peripheral neuropathy treatments. The autonomic segment is also expected to demonstrate strong growth due to the increasing diabetic population and demand for safe and effective therapies.

By Drug Class

The market includes non-steroidal anti-inflammatory drugs, opioids, antidepressants, anti-seizure medications, and others. Non-steroidal anti-inflammatory drugs held a leading position due to their widespread use for managing pain and inflammation. The opioid segment is expected to experience notable growth as new pain-management formulations and therapies become available.

By Distribution Channel

The market is divided into hospital pharmacies, retail pharmacies and stores, and online pharmacies. Hospital pharmacies accounted for 46.2% in 2025, supported by the increasing number of diabetic patients receiving routine monitoring and treatment in hospitals. Online pharmacies are also gaining importance because they provide convenient access to medications.

Regional Insights

North America

North America remained the leading regional market, supported by high diabetes prevalence, advanced healthcare infrastructure, early adoption of innovative therapies, and strong pharmaceutical development. The U.S. accounted for a substantial portion of regional demand, supported by a large diagnosed diabetic population.

Europe

Europe represented the second-largest regional contributor. Rising healthcare expenditure, an aging population, increasing diabetes prevalence, and pharmaceutical research activities are supporting market development. The region is expected to maintain steady growth as awareness of diabetic complications increases.

Asia Pacific

Asia Pacific is anticipated to be the fastest-growing region due to the increasing prevalence of diabetes, obesity-related complications, improving healthcare infrastructure, government awareness initiatives, and growing adoption of advanced medicines. China is expected to record strong market expansion.

Japan

Japan represents an important market because of its aging population and increasing incidence of diabetes. The diabetic neuropathy market in Japan is expected to reach USD 218.3 million by 2025, supported by growing demand for effective neuropathic pain treatments.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa are expected to experience gradual development. Healthcare infrastructure limitations, lower awareness, and restricted funding remain challenges, although improving healthcare access and diabetes-management initiatives could create future opportunities.

Competitive Landscape

Leading companies operating in the diabetic neuropathy market include Eli Lilly and Company, Pfizer Inc., Abbott, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., and Astellas Pharma US, Inc. Eli Lilly and Company and Pfizer Inc. maintain strong positions through established therapeutic portfolios and continued product development.

Key Industry Developments

In April 2019, Daiichi Sankyo launched Tarlige tablets, containing mirogabalin besilate, for peripheral neuropathic pain treatment in Japan. In October 2018, Ionis Pharmaceuticals and Akcea Therapeutics initiated a Phase III clinical trial of AKCEA-TTR-L for polyneuropathy associated with hereditary TTR amyloidosis.

Report Coverage

The diabetic neuropathy market report covers market segmentation by disease type, drug class, and distribution channel, along with regional analysis and competitive assessment. It evaluates major growth drivers, restraints, emerging treatment technologies, product launches, research and development activities, and changing treatment preferences. The report also highlights major companies and important industry developments influencing the market through 2034.

Conclusion

The diabetic neuropathy market size is expected to expand from USD 5.15 billion in 2025 to USD 5.60 billion in 2026 and USD 11.06 billion by 2034. Rising diabetes prevalence, increasing awareness of nerve-related complications, advanced drug-delivery technologies, and expanding pharmaceutical research are expected to remain central to market development. North America currently leads the market, while Asia Pacific offers significant growth opportunities due to its expanding diabetic population and improving healthcare awareness.

Unit Value (USD billion)

Segmentation By Disease Type

  • Peripheral
  • Autonomic
  • Proximal
  • Focal

By Drug Class

  • Non-Steroidal Anti-Inflammatory Drugs
  • Opioid
  • Anti-Depressants
  • Anti-Seizure
  • Others

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies & Stores
  • Online Pharmacies

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
  • 4.2. New Product Launches
  • 4.3. Prevalence of Diabetic Neuropathy
  • 4.4. Pipeline Analysis

5. Global Diabetic Neuropathy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Disease Type
    • 5.2.1. Peripheral
    • 5.2.2. Autonomic
    • 5.2.3. Proximal
    • 5.2.4. Focal
  • 5.3. Market Analysis, Insights and Forecast - By Drug Class
    • 5.3.1. Non-Steroidal Anti-Inflammatory Drugs
    • 5.3.2. Opioid
    • 5.3.3. Anti-Depressants
    • 5.3.4. Anti-Seizure
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospitals Pharmacies
    • 5.4.2. Retail Pharmacies & Stores
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Country
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Diabetic Neuropathy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Disease Type
    • 6.2.1. Peripheral
    • 6.2.2. Autonomic
    • 6.2.3. Proximal
    • 6.2.4. Focal
  • 6.3. Market Analysis - By Drug Class
    • 6.3.1. Non-Steroidal Anti-Inflammatory Drugs
    • 6.3.2. Opioid
    • 6.3.3. Anti-Depressants
    • 6.3.4. Anti-Seizure
    • 6.3.5. Others
  • 6.4. Market Analysis - By Distribution Channel
    • 6.4.1. Hospitals Pharmacies
    • 6.4.2. Retail Pharmacies & Stores
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Diabetic Neuropathy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Disease Type
    • 7.2.1. Peripheral
    • 7.2.2. Autonomic
    • 7.2.3. Proximal
    • 7.2.4. Focal
  • 7.3. Market Analysis - By Drug Class
    • 7.3.1. Non-Steroidal Anti-Inflammatory Drugs
    • 7.3.2. Opioid
    • 7.3.3. Anti-Depressants
    • 7.3.4. Anti-Seizure
    • 7.3.5. Others
  • 7.4. Market Analysis - By Distribution Channel
    • 7.4.1. Hospitals Pharmacies
    • 7.4.2. Retail Pharmacies & Stores
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis - By Country/ sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Diabetic Neuropathy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Disease Type
    • 8.2.1. Peripheral
    • 8.2.2. Autonomic
    • 8.2.3. Proximal
    • 8.2.4. Focal
  • 8.3. Market Analysis - By Drug Class
    • 8.3.1. Non-Steroidal Anti-Inflammatory Drugs
    • 8.3.2. Opioid
    • 8.3.3. Anti-Depressants
    • 8.3.4. Anti-Seizure
    • 8.3.5. Others
  • 8.4. Market Analysis - By Distribution Channel
    • 8.4.1. Hospitals Pharmacies
    • 8.4.2. Retail Pharmacies & Stores
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis - By Country/ sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Diabetic Neuropathy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Disease Type
    • 9.2.1. Peripheral
    • 9.2.2. Autonomic
    • 9.2.3. Proximal
    • 9.2.4. Focal
  • 9.3. Market Analysis - By Drug Class
    • 9.3.1. Non-Steroidal Anti-Inflammatory Drugs
    • 9.3.2. Opioid
    • 9.3.3. Anti-Depressants
    • 9.3.4. Anti-Seizure
    • 9.3.5. Others
  • 9.4. Market Analysis - By Distribution Channel
    • 9.4.1. Hospitals Pharmacies
    • 9.4.2. Retail Pharmacies & Stores
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis - By Country/ sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Diabetic Neuropathy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Disease Type
    • 10.2.1. Peripheral
    • 10.2.2. Autonomic
    • 10.2.3. Proximal
    • 10.2.4. Focal
  • 10.3. Market Analysis - By Drug Class
    • 10.3.1. Non-Steroidal Anti-Inflammatory Drugs
    • 10.3.2. Opioid
    • 10.3.3. Anti-Depressants
    • 10.3.4. Anti-Seizure
    • 10.3.5. Others
  • 10.4. Market Analysis - By Distribution Channel
    • 10.4.1. Hospitals Pharmacies
    • 10.4.2. Retail Pharmacies & Stores
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis - By Country/ sub-region
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
  • 11.5. Company Profiles
    • 11.5.1. Abbott
      • 11.5.1.1. Overview,
      • 11.5.1.2. Products & services,
      • 11.5.1.3. SWOT analysis,
      • 11.5.1.4. Recent developments,
      • 11.5.1.5. strategies,
      • 11.5.1.6. financials (based on availability)
    • 11.5.2. Eli Lilly and Company
      • 11.5.2.1. Overview,
      • 11.5.2.2. Products & services,
      • 11.5.2.3. SWOT analysis,
      • 11.5.2.4. Recent developments,
      • 11.5.2.5. strategies,
      • 11.5.2.6. financials (based on availability)
    • 11.5.3. Pfizer.Inc
      • 11.5.3.1. Overview,
      • 11.5.3.2. Products & services,
      • 11.5.3.3. SWOT analysis,
      • 11.5.3.4. Recent developments,
      • 11.5.3.5. strategies,
      • 11.5.3.6. financials (based on availability)
    • 11.5.4. F. Hoffmann-La Roche Ltd
      • 11.5.4.1. Overview,
      • 11.5.4.2. Products & services,
      • 11.5.4.3. SWOT analysis,
      • 11.5.4.4. Recent developments,
      • 11.5.4.5. strategies,
      • 11.5.4.6. financials (based on availability)
    • 11.5.5. GlaxoSmithKline plc.
      • 11.5.5.1. Overview,
      • 11.5.5.2. Products & services,
      • 11.5.5.3. SWOT analysis,
      • 11.5.5.4. Recent developments,
      • 11.5.5.5. strategies,
      • 11.5.5.6. financials (based on availability)
    • 11.5.6. Janssen Pharmaceuticals, Inc.
      • 11.5.6.1. Overview,
      • 11.5.6.2. Products & services,
      • 11.5.6.3. SWOT analysis,
      • 11.5.6.4. Recent developments,
      • 11.5.6.5. strategies,
      • 11.5.6.6. financials (based on availability)
    • 11.5.7. Lupin Pharmaceuticals, Inc.
      • 11.5.7.1. Overview,
      • 11.5.7.2. Products & services,
      • 11.5.7.3. SWOT analysis,
      • 11.5.7.4. Recent developments,
      • 11.5.7.5. strategies,
      • 11.5.7.6. financials (based on availability)
    • 11.5.8. Astellas Pharma US, Inc.
      • 11.5.8.1. Overview,
      • 11.5.8.2. Products & services,
      • 11.5.8.3. SWOT analysis,
      • 11.5.8.4. Recent developments,
      • 11.5.8.5. strategies,
      • 11.5.8.6. financials (based on availability)
    • 11.5.9. Other Prominent Players
      • 11.5.9.1. Overview,
      • 11.5.9.2. Products & services,
      • 11.5.9.3. SWOT analysis,
      • 11.5.9.4. Recent developments,
      • 11.5.9.5. strategies,
      • 11.5.9.6. financials (based on availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Disease Type, 2021-2034
  • Table 2: Global Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 3: Global Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Region, 2021-2034
  • Table 5: North America Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Disease Type, 2021-2034
  • Table 6: North America Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, By Country, 2021-2034
  • Table 9: Europe Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Disease Type, 2021-2034
  • Table 10: Europe Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 11: Europe Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Disease Type, 2021-2034
  • Table 14: Asia Pacific Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 15: Asia Pacific Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Disease Type, 2021-2034
  • Table 18: Latin America Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 19: Latin America Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Disease Type, 2021-2034
  • Table 22: Middle East & Africa Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 23: Middle East & Africa Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Diabetic Neuropathy Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Diabetic Neuropathy Market Revenue Breakdown (US$ Bn, %) by Region, 2025 & 2034
  • Figure 2: Global Diabetic Neuropathy Market Value Share (%), by Disease Type, 2025 & 2034
  • Figure 3: Global Diabetic Neuropathy Market Forecast (US$ Bn), by Peripheral, 2025-2034
  • Figure 4: Global Diabetic Neuropathy Market Forecast (US$ Bn), by Autonomic, 2025-2034
  • Figure 5: Global Diabetic Neuropathy Market Forecast (US$ Bn), by Proximal, 2025-2034
  • Figure 6: Global Diabetic Neuropathy Market Forecast (US$ Bn), by Focal, 2025-2034
  • Figure 7: Global Diabetic Neuropathy Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 8: Global Diabetic Neuropathy Market Forecast (US$ Bn), by Non-Steroidal Anti-Inflammatory Drugs, 2025-2034
  • Figure 9: Global Diabetic Neuropathy Market Forecast (US$ Bn), by Opioid, 2025-2034
  • Figure 10: Global Diabetic Neuropathy Market Forecast (US$ Bn), by Anti-Depressants, 2025-2034
  • Figure 11: Global Diabetic Neuropathy Market Forecast (US$ Bn), by Anti-Seizure, 2025-2034
  • Figure 12: Global Diabetic Neuropathy Market Forecast (US$ Bn), by Others, 2025-2034
  • Figure 13: Global Diabetic Neuropathy Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 14: Global Diabetic Neuropathy Market Forecast (US$ Bn), by Hospitals Pharmacies, 2025-2034
  • Figure 15: Global Diabetic Neuropathy Market Forecast (US$ Bn), by Retail Pharmacies & Stores, 2025-2034
  • Figure 16: Global Diabetic Neuropathy Market Forecast (US$ Bn), by Online Pharmacies, 2025-2034
  • Figure 17: Global Diabetic Neuropathy Market Value (US$ Bn), by Region, 2025 & 2034
  • Figure 18: North America Diabetic Neuropathy Market Value (US$ Bn), by Disease Type, 2025 & 2034
  • Figure 19: North America Diabetic Neuropathy Market Value Share (%), by Disease Type, 2025
  • Figure 20: North America Diabetic Neuropathy Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 21: North America Diabetic Neuropathy Market Value Share (%), by Drug Class, 2025
  • Figure 22: North America Diabetic Neuropathy Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 23: North America Diabetic Neuropathy Market Value Share (%), by Distribution Channel, 2025
  • Figure 24: North America Diabetic Neuropathy Market Value (US$ Bn), By Country, 2025 & 2034
  • Figure 25: North America Diabetic Neuropathy Market Value Share (%), By Country, 2025
  • Figure 26: Europe Diabetic Neuropathy Market Value (US$ Bn), by Disease Type, 2025 & 2034
  • Figure 27: Europe Diabetic Neuropathy Market Value Share (%), by Disease Type, 2025
  • Figure 28: Europe Diabetic Neuropathy Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 29: Europe Diabetic Neuropathy Market Value Share (%), by Drug Class, 2025
  • Figure 30: Europe Diabetic Neuropathy Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 31: Europe Diabetic Neuropathy Market Value Share (%), by Distribution Channel, 2025
  • Figure 32: Europe Diabetic Neuropathy Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
  • Figure 33: Europe Diabetic Neuropathy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 34: Asia Pacific Diabetic Neuropathy Market Value (US$ Bn), by Disease Type, 2025 & 2034
  • Figure 35: Asia Pacific Diabetic Neuropathy Market Value Share (%), by Disease Type, 2025
  • Figure 36: Asia Pacific Diabetic Neuropathy Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 37: Asia Pacific Diabetic Neuropathy Market Value Share (%), by Drug Class, 2025
  • Figure 38: Asia Pacific Diabetic Neuropathy Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 39: Asia Pacific Diabetic Neuropathy Market Value Share (%), by Distribution Channel, 2025
  • Figure 40: Asia Pacific Diabetic Neuropathy Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
  • Figure 41: Asia Pacific Diabetic Neuropathy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 42: Latin America Diabetic Neuropathy Market Value (US$ Bn), by Disease Type, 2025 & 2034
  • Figure 43: Latin America Diabetic Neuropathy Market Value Share (%), by Disease Type, 2025
  • Figure 44: Latin America Diabetic Neuropathy Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 45: Latin America Diabetic Neuropathy Market Value Share (%), by Drug Class, 2025
  • Figure 46: Latin America Diabetic Neuropathy Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 47: Latin America Diabetic Neuropathy Market Value Share (%), by Distribution Channel, 2025
  • Figure 48: Latin America Diabetic Neuropathy Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
  • Figure 49: Latin America Diabetic Neuropathy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 50: Middle East & Africa Diabetic Neuropathy Market Value (US$ Bn), by Disease Type, 2025 & 2034
  • Figure 51: Middle East & Africa Diabetic Neuropathy Market Value Share (%), by Disease Type, 2025
  • Figure 52: Middle East & Africa Diabetic Neuropathy Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 53: Middle East & Africa Diabetic Neuropathy Market Value Share (%), by Drug Class, 2025
  • Figure 54: Middle East & Africa Diabetic Neuropathy Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 55: Middle East & Africa Diabetic Neuropathy Market Value Share (%), by Distribution Channel, 2025
  • Figure 56: Middle East & Africa Diabetic Neuropathy Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
  • Figure 57: Middle East & Africa Diabetic Neuropathy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 58: Global Diabetic Neuropathy Market Share (%), By Company, 2025